

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **CCP110 RABBIT PAB**

货号: S221858 产品全名: CCP110 兔多抗 基因符号 CP110; Cep110 UNIPROT ID: 043303 (Gene Accession - NP\_055526)

背景: Necessary for centrosome duplication at different stages of procentriole formation. Acts as a key negative regulator of ciliogenesis in collaboration with CEP97 by capping the mother centriole thereby preventing cilia formation (PubMed:17719545 PubMed:17681131, PubMed:23486064). Also involved in promoting ciliogenesis. May play a role in the assembly of the mother centriole subdistal appendages (SDA) thereby effecting the fusion of recycling endosomes to basal bodies during cilia formation (By similarity). Required for correct spindle formation and has a role in regulating cytokinesis and genome stability via cooperation with CALM1 and CETN2 (PubMed:16760425).

抗原: Synthetic peptide of human CCP110

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 20-100; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse

成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


研究领域: Cancer

储存和运输: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human brain In comparision with the IHC on the left, the same paraffin-embedded tissue using 221858(CCP110 Antibody) at a dilution of 1/20(Cytoplasm)

Human brain tissue is first treated with the synthetic peptide and then with 221858(Anti-CCP110 Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffinembedded Human esophagus cancer tissue using 221858(Anti-CCP110 Antibody) at a dilution of 1/20.

In comparision with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with synthetic peptide and then with D263637(Anti-CCP110 Antibody) at dilution



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010